Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.
-
O'Mahony ET, Arian CM, Aryeh KS, Wang K, Thummel KE, Kelly EJ. Human intestinal enteroids: Nonclinical applications for predicting oral drug disposition, toxicity, and efficacy. Pharmacol Ther. 2025 Sep; 273:108879.
-
Elfawal MA, Goetz E, Kim Y, Chen P, Savinov SN, Barasa L, Thompson PR, Aroian RV. High-Throughput Screening of More Than 30,000 Compounds for Anthelmintics against Gastrointestinal Nematode Parasites. ACS Infect Dis. 2025 Jan 10; 11(1):104-120.
-
Bozal SB, Sjogren G, Costa AP, Brown JS, Roberts S, Baker D, Gabriel P, Ristau BT, Samuels M, Flynn WF, Robson P, Courtois ET. Development of an automated 3D high content cell screening platform for organoid phenotyping. SLAS Discov. 2024 10; 29(7):100182.
-
Michener PS, Knee A, Wilson D, Boama-Nyarko E, Friedmann PD. Association of random and observed urine drug screening with long-term retention in opioid treatment programs. Drug Alcohol Depend. 2024 Feb 01; 255:111067.
-
Goyenvalle A, Jimenez-Mallebrera C, van Roon W, Sewing S, Krieg AM, Arechavala-Gomeza V, Andersson P. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic Acid Ther. 2023 01; 33(1):1-16.
-
Van Ness KP, Cesar F, Yeung CK, Himmelfarb J, Kelly EJ. Microphysiological systems in absorption, distribution, metabolism, and elimination sciences. Clin Transl Sci. 2022 01; 15(1):9-42.
-
Wang EY, Kuzmanov U, Smith JB, Dou W, Rafatian N, Lai BFL, Lu RXZ, Wu Q, Yazbeck J, Zhang XO, Sun Y, Gramolini A, Radisic M. An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy. J Mol Cell Cardiol. 2021 11; 160:97-110.
-
Moore E, Reynolds JA, Davidson A, Gallucci S, Morel L, Rao DA, Young HA, Putterman C. Promise and complexity of lupus mouse models. Nat Immunol. 2021 06; 22(6):683-686.
-
Charbord J, Ren L, Sharma RB, Johansson A, ?gren R, Chu L, Tworus D, Schulz N, Charbord P, Stewart AF, Wang P, Alonso LC, Andersson O. In vivo screen identifies a SIK inhibitor that induces ? cell proliferation through a transient UPR. Nat Metab. 2021 05; 3(5):682-700.
-
Kurt Yilmaz N, Schiffer CA. Introduction: Drug Resistance. Chem Rev. 2021 03 24; 121(6):3235-3237.